PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1799613
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1799613
The Global Preimplantation Genetic Testing (PGT) Market is estimated at approximately USD 0.74 billion in 2024 and is poised to expand at a robust compound annual growth rate (CAGR) of 11.40% during the forecast period of 2025-2035. Preimplantation Genetic Testing, a critical tool in assisted reproductive technology, enables the detection of genetic abnormalities in embryos before implantation. The procedure plays a pivotal role in enhancing the success rates of in-vitro fertilization (IVF) and reducing the risk of hereditary disorders. Increasing awareness about reproductive health, rising prevalence of genetic disorders, and the growing adoption of IVF procedures globally are key drivers fueling market growth. Furthermore, technological innovations in genetic sequencing and screening have significantly broadened the capabilities and accuracy of PGT.
Rapid advancements in diagnostic and screening technologies are creating substantial opportunities for the market. Next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and single nucleotide polymorphism (SNP) technologies are increasingly being leveraged for precise embryo assessment. The surge in infertility rates, coupled with the rising maternal age at conception in developed and developing regions, has accelerated the demand for PGT procedures. According to recent statistics, over 8 million babies have been born worldwide through IVF techniques, highlighting a growing patient pool for preimplantation genetic testing. Nevertheless, high costs associated with these procedures and limited awareness in underdeveloped regions could restrain market penetration to some extent during 2025-2035.
From a regional standpoint, North America is projected to hold a dominant position due to the presence of advanced healthcare infrastructure, early adoption of innovative reproductive technologies, and strong research initiatives in genetic testing. Europe, driven by increasing fertility clinics and government initiatives supporting IVF and genetic testing, also constitutes a significant share of the market. The Asia Pacific region is anticipated to witness the fastest growth during the forecast period, fueled by surging infertility rates, rising disposable income, expanding IVF centers, and the growing awareness regarding genetic disorders in countries like China, India, and Japan. Latin America and the Middle East & Africa are emerging markets, benefiting from increasing fertility tourism and government support for assisted reproductive technologies.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.